Switching Anticoagulation: From Vitamin K Antagonists to DOACs
Switching Anticoagulant Treatment:
The use of direct oral anticoagulants (DOACs) has progressively replaced vitamin K antagonists (VKAs), such as acenocoumarol and warfarin, in the management of non-valvular atrial fibrillation (NVAF). The accumulated evidence supports their safety and efficacy, simplifying anticoagulation without the need for monitoring of the INR. However, switching from a VKA to a DOAC must be done in a structured way to minimise thrombotic and bleeding risks.

Switching Anticoagulant Treatment. Indications for Switching From VKA to DOAC
Switching to a DOAC is recommended in patients with NVAF in the following scenarios:
- Labile or hard-to-control INR.
- High risk of bleeding on a VKA.
- Patients who find it hard to attend regular INR checks.
- Patient preference for a more stable anticoagulation regimen without frequent monitoring.
Strategy for Switching From Sintrom/Warfarin to a DOAC
The best time to start a DOAC depends on the patient's INR:
- If the INR is <2.0, start the DOAC immediately.
- If the INR is between 2.0-2.5, the DOAC can be started the same day or the next day.
- If the INR is >2.5, it is recommended to wait until the INR falls below 2.5 before starting the DOAC, to avoid an excessive anticoagulant effect.
Here is a helpful post on which DOAC to start and at what dose for each patient.
Pharmacological and Clinical Considerations
- Pharmacokinetic differences: Unlike VKAs, DOACs have a rapid onset of action (2-4 hours) and a shorter half-life, which allows more predictable adjustments.
- Drug interactions: DOACs have fewer food and drug interactions than VKAs. However, interactions with CYP3A4 and P-glycoprotein inhibitors and inducers must be considered.
- Kidney function: Renal impairment influences the choice of DOAC and its dose. It is essential to assess the glomerular filtration rate (GFR) before starting treatment.
Follow-up and Assessment After Switching
Initial follow-up after switching from a VKA to a DOAC should include:
- Assessment of adherence and tolerability.
- Periodic monitoring of kidney and liver function.
- Teaching the patient about the importance of adherence and how to recognise signs of bleeding.
References
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, European Heart Journal, Volume 39, Issue 16, 21 April 2018, Pages 1330–1393






